• Events
    • EURETINA 2024 Barcelona
      • Programme Submission Terms
      • Submit Programme Abstract
    • EURETINA 2023 Amsterdam
      • Amsterdam On Demand
      • Congress Daily
      • Congress Photo Gallery
      • Information
      • Programme
      • Abstracts
      • Late Breaking
      • Hotels
      • Registration
      • Exhibition Bookings
      • EURETINA Innovation Spotlight (EIS)
    • EURETINA Innovation Spotlight (EIS)
      • Information
      • Programme
      • Contributors
      • Registration
      • Sponsorship
      • Industry Abstracts
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Hotels
      • Exhibition Information
      • Abstract Viewer
    • EURETINA 2022 Hamburg
      • On Demand
      • Sustainability Plan
      • Programme Overview
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Abstract Viewer
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
      • Seeing is Believing Collection
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • EURETINA 2024 Barcelona
      • Programme Submission Terms
      • Submit Programme Abstract
    • EURETINA 2023 Amsterdam
      • Amsterdam On Demand
      • Congress Daily
      • Congress Photo Gallery
      • Information
      • Programme
      • Abstracts
      • Late Breaking
      • Hotels
      • Registration
      • Exhibition Bookings
      • EURETINA Innovation Spotlight (EIS)
    • EURETINA Innovation Spotlight (EIS)
      • Information
      • Programme
      • Contributors
      • Registration
      • Sponsorship
      • Industry Abstracts
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Hotels
      • Exhibition Information
      • Abstract Viewer
    • EURETINA 2022 Hamburg
      • On Demand
      • Sustainability Plan
      • Programme Overview
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Abstract Viewer
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
      • Seeing is Believing Collection
    • YOURS
    • CME Credits
  • Member Login
  • August 26, 2022
  • 2022 Abstracts

KSI-301 Anti-VEGF Antibody Biopolymer Conjugate for Retinal Vein Occlusion: Primary 24-Week Efficacy and Safety Outcomes of the BEACON Phase III Pivotal Study

Author: Arshad Khanani

Co-authors: Jason S Ehrlich, Daniel Janer, Pablo Velazquez-Martin, Rezi Zawadzki, Victor Perlroth

Abstract

Purpose: Vascular endothelial growth factor (VEGF) suppression therapy is the first-line treatment for macular edema (ME) secondary to retinal vein occlusion(RVO). Substantial functional and anatomic improvements can be achievedusing currently approved dosing regimens of anti-VEGFs. However, increased treatment burden continues to prevent good outcomes from being consistently achieved in the clinical setting.KSI-301 is an antibody biopolymer conjugate (ABC) designed to providesafe and longer-lasting intraocular VEGF suppression.The objective of the BEACON study is to demonstrate that KSI-301 is non-inferior to aflibercept while providing a clinically meaningful reduction intreatment burden for patients with ME secondary to RVO.

Setting: A Phase 3 prospective, randomized, double-masked, two-arm, multi-centernon-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg vs aflibercept 2 mg in participants with visual impairment due to treatment-naÔve macular edema secondary to RVO.

Methods: Treatment-naÔve patients with ME secondary to branch or central RVOwere randomized 1:1 into two treatment arms: aflibercept 2 mg dosedmonthly or KSI-301 5 mg dosed every eight weeks (Q8W) after two initialmonthly doses. The primary efficacy endpoint is the mean change in best corrected visual acuity (BCVA) at Week 24. Secondary endpoints at Week 24 include change from baseline in retinal thickness measured by optical coherence tomography (OCT) central subfield thickness (CST), the proportions of patients gaining or losing ?10 or ?15 ETDRS letters from baseline, and the incidence of ocular and non-ocular adverse events.Starting at Week 24 through the end of the study, patients in both treatmentarms are evaluated monthly and treated according to protocol defined disease activity criteria.

Results: 134 sites across the United States, Europe and Israel randomized 568 patients (279 females, 49.1%) into the study with a mean age of 65.3 years. At baseline, mean BCVA was 60.4 letters with 32% of patientshaving a Snellen equivalent of 20/40 or better; mean baseline CST was 577.4 um. Results for the primary endpoint will be presented for the first time at the meeting.

Conclusions: Patients with treatment naÔve ME secondary to RVO can achieve substantial improvements in function and anatomy when treated with monthly dosing of currently available anti-VEGF therapies. However, this high treatment burden imposed on patients, caregivers, clinicians and the healthcare system prevents a significant proportion of patients fromachieving and maintaining these outcomes in the clinical setting. The ABC platform leverages the unique biophysical properties of branched phosphorylcholine biopolymers to maintain effective therapeutic levels of a biologic, such as an anti-VEGF antibody, for longer periods of time inside the eye, for this reason KSI-301 has the potential to address this unmet medical need. Data on the Week 24 primary efficacy outcomes will bepresented for the first time at the EURETINA meeting.

Financial Disclosure: Research grant from Kodiak Sciences. Consultant for Kodiak Sciences.
PrevPrevious
NextNext

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2023 Amsterdam

EURETINA Innovation Spotlight (EIS)

Abstract Viewer

Ophthalmologica

Forum

Opportunities

Memberships

About

Privacy Policy

Contact Us

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2023 All rights reserved

  • Events
    • EURETINA 2024 Barcelona
      • Programme Submission Terms
      • Submit Programme Abstract
    • EURETINA 2023 Amsterdam
      • Amsterdam On Demand
      • Congress Daily
      • Congress Photo Gallery
      • Information
      • Programme
      • Abstracts
      • Late Breaking
      • Hotels
      • Registration
      • Exhibition Bookings
      • EURETINA Innovation Spotlight (EIS)
    • EURETINA Innovation Spotlight (EIS)
      • Information
      • Programme
      • Contributors
      • Registration
      • Sponsorship
      • Industry Abstracts
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Hotels
      • Exhibition Information
      • Abstract Viewer
    • EURETINA 2022 Hamburg
      • On Demand
      • Sustainability Plan
      • Programme Overview
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Abstract Viewer
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
      • Seeing is Believing Collection
    • YOURS
    • CME Credits
  • Member Login